Asian Pacific Journal of Cancer Prevention

Asian Pacific Journal of Cancer Prevention (아시아태평양암예방학회)
권호 표지
DOI QR코드

DOI QR Code

Improved Diagnostic Accuracy of Pancreatic Diseases with a Combination of Various Novel Serum Biomarkers - Case Control Study from Manipal Teaching Hospital, Pokhara, Nepal

  • Published : 2012.05.30
Download PDF
⟨ Previous Next ⟩

Abstract

Background: Pancreatic cancer is a distressing disease with a miserable prospects and early recognition remains a challenge due to ubiquitous symptomatic presentation, deep anatomical location, and aggressive etiology. False positives and problems in distinguishing pancreatitis from adenocarcinoma limit the use of CA 19-9 as both disorders can present with similar symptoms and share radiographic physiognomies. This study aimed to assess the relative increase in accuracy of diagnosing the patients with chronic pancreatitis, benign neoplasm of pancreas and adenocarcinomas with CA 19-9, haptoglobin, and serum amyloid A in comparison to CA 19-9 alone. Materials and Methods: This hospital based case control study was carried out in the Departments of Medicine and Biochemistry of Manipal Teaching Hospital, Pokhara, Nepal, between $1^{st}$ January 2010 and $31^{st}$ December 2011. The variables assessed were age, gender, serum CA19-9, serum haptoglobulin, serum Amyloid A. The data were analyzed using Excel 2003, R 2.8.0 Statistical Package for the Social Sciences (SPSS) for Windows Version 16.0 (SPSS Inc; Chicago, IL, USA) and the EPI Info 3.5.1 Windows Version. Results: Out of 197 cases of pancreatic disease, maximum number of assumed cases were of adenocarcinoma of pancreas (95). Number of males (59) were more than females (36) in assumed cases of adenocarcinoma of pancreas. The mean values of CA19-9 raised considerably in cases of chronic pancreatitis, benign neoplasm and adenocarcinoma of pancreas when compared to controls. The highest augmention in CA19-9 values were in cases of adenocarcinoma of pancreas. The p-value indicates that in cases of chronic pancreatitis, there was not significant increase in precision of diagnosis. Conclusions: These statistics established that haptoglobin and SAA are useful in discriminating cancer from benign conditions as well as healthy controls.

Keywords

References

  1. Benson AB (2007). Adjuvant therapy for pancreatic cancer, one small step forward. JAMA, 297, 311-3. https://doi.org/10.1001/jama.297.3.311
  2. Biran H, Friedman N, Neumann L, Pras M, Shainkin- Kestenbaum R (1999). Serum amyloid A (SAA) variations in patients with cancer: correlation with disease activity, stage, primary site, and prognosis. Clin Chem Lab Med, 37,381-3.
  3. Boll DT, Merkle EM (2003). Differentiating a chronic hyperplastic mass from pancreatic cancer: a challenge remaining in multidetector CT of the pancreas. Eur Radiol, 13, 42-9. https://doi.org/10.1007/BF03323622
  4. Brand RE, Nolen BM, Zeh HJ, et al (2011). Serum biomarker panels for the detection of pancreatic cancer. Clin Cancer Res, 17, 805-16. https://doi.org/10.1158/1078-0432.CCR-10-0248
  5. Greenlee RT, Murray T, Bolden S, Wingo PA (2000). Cancer statistics, 2000. CA Cancer J Clin, 50, 7-33. https://doi.org/10.3322/canjclin.50.1.7
  6. Katz MH, Hwang R, Fleming JB et al (2008). Tumor-nodemetastasis staging ofpancreatic adenocarcinoma. CA Cancer J Clin, 58, 111-25. https://doi.org/10.3322/CA.2007.0012
  7. Kushner I (1994). The acute phase response. Immunol Today, 15, 72-80.
  8. Narisada M, Kawamoto S, Kuwamoto K, et al (2008). Identification of an inducible factor secreted by pancreatic cancer cell lines that stimulates the production of fucosylated haptoglobin in hepatoma cells. Biochem Biophys Res Commun, 377, 792-6. https://doi.org/10.1016/j.bbrc.2008.10.061
  9. Okuyama N, Ide Y, Nakano M, et al (2006). Fucosylated haptoglobin is a novel marker for pancreatic cancer: a detailed analysis of the oligosaccharide structure and a possible mechanism for fucosylation. Int J Cancer, 118, 2803-8. https://doi.org/10.1002/ijc.21728
  10. Owen JA, Better FC, Hoban J (1960). A simple method for the determination of serum haptoglobins. J ClinPathol, 13, 163-4.
  11. Raimondi S, Lowenfels AB, Morselli-Labate AM, Maisonneuve P, Pezzilli R (2010). Pancreatic cancer in chronic pancreatitis; aetiology, incidence, and early detection. Best Pract Res Clin Gastroenterol, 24, 349-58. https://doi.org/10.1016/j.bpg.2010.02.007
  12. Rocha ULJ, Sanchez AVM, Esquete PJ, et al (2007). Evaluation of the Bilio-Pancreatic Region Using Endoscopic Ultrasonography in Patients Referred with and without Abdominal Pain and CA 19-9 Serum Level Elevation. J Pancreas, 8, 191-7.
  13. Sell LS (1990). Cancer markers of the 1990s. Clin Lab Med, 10, 1-37.
  14. Shrikhande SV, Barreto G, Koliopanos A (2009). Pancreatic carcinogenesis: The impact of chronic pancreatitis and its clinical relevance. Indian J Cancer, 46, 288-96. https://doi.org/10.4103/0019-509X.55548

Cited by

  1. Serum Amyloid A is a Novel Prognostic Biomarker in Hepatocellular Carcinoma vol.15, pp.24, 2014, https://doi.org/10.7314/APJCP.2014.15.24.10713